Citations should be made in the following way: Authors. Title. Eur Respir J 2015; 46: Suppl. 59, abstract number.
Citations should be made in the following way: Authors. Title. Eur Respir J 2015; 46: Suppl. 59, abstract number.
Treatment of idiopathic pulmonary fibrosis
Lunchtime sessionChairs: Henk C. Hoogsteden (Rotterdam, Netherlands), Fernando J. Martinez (Ann Arbor, United States of America)
Aims: To provide the knowledge needed to better understand the published results of several clinical trials that assess the safety and efficacy of various treatment regimens in IPF. The audience will also become aware of the implications of the new evidence-based recommendations for IPF that were generated by a panel of international experts who did not have conflicts of interest. This panel included methodologists who were experienced in reviewing evidence and developing evidence-based guidelines, general pulmonologists, internists and a patient representative. The panel made their recommendations after discussing the evidence in the presence of conflicted experienced IPF experts. By the end of the session, the audience will be able to make a well-informed decision regarding the treatment options for patients with IPF; they will also be able use the new treatment recommendations on the basis of scientific evidence. Moreover, they will have gained an appreciation for the knowns and unknowns associated with each treatment recommendation and the need for further clinical studies/trials on existing and new therapeutic interventions for IPF.
Target audience: Pulmonologists, clinicians, healthcare providers, respiratory function technologists, clinical investigators, scientists, regulatory agencies, policy makers, patients, healthcare givers, pharmaceutical industries and sponsors.